North America Non-Small Cell Lung Cancer Diagnostics Market – Industry Trends and Forecast to 2028

Market Analysis and Insights: North America Non-Small Cell Lung Cancer Diagnostics Market

The North America non-small cell lung cancer diagnostics market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 13.0% in the forecast period of 2021 to 2028 and is expected to reach USD 1,440.42 million by 2028.

Non-small cell lung cancer is a diseases in which malignant cells or cancer cells are formed in the tissues of lungs. These are of different types and each type has different cancer cells that grow and spread in different ways. The non-small cell lung cancer (NSCLC) type are squamous cell carcinoma, large cell carcinoma and adennocarcinoma. In squamous cell carcinoma, the cancer forms in the thin, flat cells lining inside the lungs and are also called epidermoid carcinoma, large cell carcinoma cancer begins in several types of large cells and adenocarcinoma type of cancer begins in the cells which line the alveoli and make substance such as mucus. One of the major risks for non-small cell lung cancer (NSCLC) is that smoking and symptoms include cough, which doesn’t go away and shortness of breath. Various tests are used, such as imaging test, molecular test, biopsy, and others, to diagnose and examine the cancer stage. Diagnosis is important to identify the disease in time so that proper treatment could be given

The factors driving the growth of the non-small cell lung cancer diagnostics market are the usage of rise in number of elder aged population that is more susceptible to non-small cell lung cancer while high competition in the market among the local and global players may restrain the non-small cell lung cancer diagnostics market growth.

The non-small cell lung cancer diagnostics market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the machine vision logistics market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

North America Non-Small Cell Lung Cancer Diagnostics Market Scope and Market Size

The North America non-small cell lung cancer diagnostics market is segmented into four notable segments based on the lung cancer type, product, test and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of cancer type, the North America non-small cell lung cancer diagnostics market is segmented into lung adenocarcinoma (LUAD), lung squamous cellcarcinoma (LUSC), large cell carcinoma and others. In 2021, the lung adenocarcinoma (LUAD) segment is expected to dominate the non-small cell lung cancer diagnostics market due to the high prevalence of the Lung Adenocarcinoma among all type of non-small cell lung cancer.
• On the basis of product, the North America non-small cell lung cancer diagnostics market is segmented into reagents & kits, instruments and services & softwares. In 2021, the instrument segment is expected to dominate the non-small cell lung cancer diagnostics market due to the availability of the instrument along with advancement in the technology.
• On the basis of test, the North America non-small cell lung cancer diagnostics market is segmented imaging test, molecular test, biopsy, sputum cytology, thoracentesis, immunohistochemistry and others. In 2021, the molecular test segment is expected to dominate the non-small cell lung cancer diagnostics market due to rising need of molecular tests to diagnose non-small cell lung cancer accurately and efficiently.
• On the basis of end user, the North America non-small cell lung cancer diagnostics market is segmented into hospital, clinical laboratories, academics and others. In 2021, the clinical laboratories segment is expected to dominate the non-small cell lung cancer diagnostics market due to the growing clinical research in cancer.

North America Non-Small Cell Lung Cancer Diagnostics Market: Country Level Analysis

North America non-small cell lung cancer diagnostics market is analyzed and market size information is provided by country, lung cancer type, products, test and end user.

Countries covered in the North America Non-small cell lung cancer diagnostics market report are US, Canada and Mexico.

US is dominating the non-small cell lung cancer diagnostics market with the highest CAGR and highest market share due to growing cases of cancer in U.S.

In U.S., Lung Adenocarcinoma (LUAD) segment is growing due to high prevalence of lung adenocarcinoma among types of non-small cell lung cancer. In Canada, the Lung Adenocarcinoma (LUAD) segment is growing due to rise in need for molecular tests to diagnose non-small cell lung cancer accurately. In Mexico, the Lung Adenocarcinoma (LUAD) segment is growing due to advancements made in technology used in the clinical laboratory to detect molecular abnormalities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Rising Demand of Diagnostic in Medical Setting

North America non-small cell lung cancer diagnostics market also provides you with detailed market analysis for every country growth in industry with sales, components sales, impact of technological development in non-small cell lung cancer diagnostics, and changes in regulatory scenarios with their support for the non-small cell lung cancer diagnostics market. The data is available for historic period 2010 to 2019.

Competitive Landscape and North America Non-Small Cell Lung Cancer Diagnostics Market Share Analysis

North America non-small cell lung cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, India presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, and technology lifeline curve. The above data points provided are only related to the companies’ focus related to non-small cell lung cancer diagnostics market.

Some of the major players operating in the non-small cell lung cancer diagnostics market are Abbott, F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., QIAGEN, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., NanoString, Janssen Pharmaceutical NV, Inivata Ltd, bioMérieux SA, Biotheranostics, OncoCyte Corporation Inc., GENERAL ELECTRIC COMPANY, Eckert & Ziegler, DrLal PathLabs, RIVERAIN TECHNOLOGIES, PlexBio Co.,Ltd, Oncimmune, and Biodesix among others.

North America non-small cell lung cancer diagnostics market is fragmented and the major players have used various strategies such as collaborations, recognitions, agreements, and others, to increase their footprints in the non-small cell lung cancer diagnostics market.

For instance,

• In March 2021, Agilent Technologies, Inc. acquired Resolution Bioscience for USD 550 million to strengthen its business in next-generation sequencing (NGS)-based oncology solutions
• In May 2021, QIAGEN launched FDA approved therascreen KRAS RGQ PCR Kit, which aids in the identification of non-small cell lung cancer (NSCLC) in patients
• In June 2020, F. Hoffmann-La Roche Ltd launched automated digitalpathology algorithm, uPath PD-L1 (SP263) image analysis  to diagnose non-small cell lung cancer (NSCLC) and improve the speed and accuracy of diagnosis treatment

SKU-64358